Vanda Pharmaceuticals Inc. Net Income Loss

• Vanda Pharmaceuticals Inc. showed a decrease of -1,066.5% in Net Income Loss from 2024 to 2025.
• This data is from Vanda Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Vanda Pharmaceuticals Inc.'s Net Income Loss has declined by 514.8%.
• Historical annual values: Fiscal year 2025: -$220.47 million | Fiscal year 2024: -$18.90 million | Fiscal year 2023: $2.51 million | Fiscal year 2022: $6.28 million | Fiscal year 2021: $33.15 million | Fiscal year 2020: $23.34 million | Fiscal year 2019: $115.55 million | Fiscal year 2018: $25.21 million | Fiscal year 2017: -$15.57 million | Fiscal year 2016: -$18.01 million | Fiscal year 2015: -$39.87 million | Fiscal year 2014: $20.19 million | Fiscal year 2013: -$21.06 million | Fiscal year 2012: -$28.62 million | Fiscal year 2011: -$9.80 million | Fiscal year 2010: $7.19 million | Fiscal year 2009: -$35.86 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026